MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN
Source abstract
Abstract
BACKGROUND: The human cervical carcinoma oncogenic mechanisms still remain elusive. Thus, we proposed to understand the biological role of a newly discovered therapeutic miRNA. METHODS: MiR-1297 related to human cervical carcinoma was selected for this study. TaqMan qRT- PCR assay was used to profile miRNA, phosphatase and tensin homolog (PTEN) expression in randomly chosen tumour with non-tumour tissues, and the apoptosis factors expression. Cell proliferation was monitored by CCK-8 assay and colony formation assay. Apoptosis was determined by flow cytometry. Protein level was determined by western blotting. 3'UTR was performed to validate the direct binding sites of miR-1297 on PTEN. SPSS was used for statistical analyses. RESULTS: MiR-1297 is repressed and PTEN activated in human cervical cancer tissues. After miR-1297 overexpression, HeLa cells had an increase in cell proliferation and decrease in apoptosis. PTEN expression is negatively correlation with miR-1297. PTEN silencing display the similar pattern as miRNA-1297 overexpression to inhibit HeLa cell growth and apoptosis in vitro. CONCLUSIONS: Our data indicate that miR-1297 contribute to the human cervical carcinoma through PTEN. miR-1297 could be a reasonable miRNA for future studies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · PI3K/AKT/mTOR signaling in cancer · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;
Women&infants Hospital Of Zhengzhou, Zhengzhou, China;
National Institutes of Health, Bethesda, MD, USA
References (33)
Show source-provided references
1. 10.1093/nar/gkj11210.1093/nar/gkj112 ↗
2. 10.1093/oxfordjournals.jncimonographs.a00347910.1093/oxfordjournals.jncimonographs.a003479 ↗
3. 10.1038/nrm208510.1038/nrm2085 ↗
4. 10.1016/j.ejmech.2017.10.01110.1016/j.ejmech.2017.10.011 ↗
5. 10.1155/2016/608943010.1155/2016/6089430 ↗
6. 10.1177/194760191140732510.1177/1947601911407325 ↗
7. 10.1016/j.advenzreg.2006.01.00410.1016/j.advenzreg.2006.01.004 ↗
8. 10.1073/pnas.101905510810.1073/pnas.1019055108 ↗
9. 10.1080/21691401.2017.131542910.1080/21691401.2017.1315429 ↗
10. 10.1080/21691401.2017.141591810.1080/21691401.2017.1415918 ↗
11. 10.1016/j.sjbs.2018.01.01310.1016/j.sjbs.2018.01.013 ↗
12. 10.3892/etm.2014.207910.3892/etm.2014.2079 ↗
13. 10.1080/21691401.2017.136572410.1080/21691401.2017.1365724 ↗
14. Ma C · Int J Clin Exp Pathol · 2015 · 8 · 6533
15. 10.1016/j.ymeth.2014.12.02210.1016/j.ymeth.2014.12.022 ↗
16. 10.1016/j.tem.2012.11.00210.1016/j.tem.2012.11.002 ↗
17. 10.1126/scisignal.200582510.1126/scisignal.2005825 ↗
18. 10.1016/j.cell.2013.04.00310.1016/j.cell.2013.04.003 ↗
19. 10.7314/APJCP.2014.15.21.918510.7314/APJCP.2014.15.21.9185 ↗
20. 10.3892/ol.2016.532610.3892/ol.2016.5326 ↗
21. 10.1089/dna.2017.388610.1089/dna.2017.3886 ↗
22. 10.3109/14756366.2011.65411410.3109/14756366.2011.654114 ↗
23. 10.1093/carcin/bgs02210.1093/carcin/bgs022 ↗
24. 10.1354/vp.39-3-37210.1354/vp.39-3-372 ↗
25. 10.1073/pnas.060913910410.1073/pnas.0609139104 ↗
26. Yang Y · Anticancer Res · 2010 · 30 · 981
27. 10.1007/s11596-010-0206-110.1007/s11596-010-0206-1 ↗
28. 10.1038/onc.2011.49410.1038/onc.2011.494 ↗
29. 10.1007/s10549-008-0227-710.1007/s10549-008-0227-7 ↗
30. 10.1089/thy.2010.036510.1089/thy.2010.0365 ↗
31. 10.1016/j.jhep.2009.01.02710.1016/j.jhep.2009.01.027 ↗
32. 10.1016/j.bbrc.2012.09.02510.1016/j.bbrc.2012.09.025 ↗
33. 10.1038/sj.onc.120716210.1038/sj.onc.1207162 ↗